Millennium Management LLC Acquires 153,815 Shares of HilleVax, Inc. (NASDAQ:HLVX)

Millennium Management LLC boosted its position in HilleVax, Inc. (NASDAQ:HLVX - Free Report) by 59.6% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 411,820 shares of the company's stock after acquiring an additional 153,815 shares during the quarter. Millennium Management LLC owned 0.83% of HilleVax worth $852,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in HLVX. Intech Investment Management LLC acquired a new stake in shares of HilleVax in the 4th quarter valued at $26,000. SG Americas Securities LLC lifted its position in shares of HilleVax by 61.6% during the 4th quarter. SG Americas Securities LLC now owns 18,145 shares of the company's stock worth $38,000 after buying an additional 6,916 shares during the last quarter. Ieq Capital LLC boosted its stake in HilleVax by 71.1% in the fourth quarter. Ieq Capital LLC now owns 22,495 shares of the company's stock valued at $47,000 after buying an additional 9,344 shares in the last quarter. Bank of Montreal Can boosted its stake in HilleVax by 47.1% in the fourth quarter. Bank of Montreal Can now owns 35,763 shares of the company's stock valued at $74,000 after buying an additional 11,459 shares in the last quarter. Finally, Russell Investments Group Ltd. grew its position in HilleVax by 328.0% in the fourth quarter. Russell Investments Group Ltd. now owns 38,236 shares of the company's stock valued at $79,000 after acquiring an additional 29,303 shares during the last quarter. 86.42% of the stock is currently owned by institutional investors and hedge funds.

HilleVax Stock Down 4.4%

Shares of NASDAQ:HLVX traded down $0.09 during trading on Tuesday, hitting $1.95. 412,375 shares of the company were exchanged, compared to its average volume of 447,679. HilleVax, Inc. has a 1-year low of $1.34 and a 1-year high of $15.60. The company has a market capitalization of $97.77 million, a P/E ratio of -0.63 and a beta of 0.74. The business's 50 day moving average is $1.82 and its 200-day moving average is $1.85.

HilleVax (NASDAQ:HLVX - Get Free Report) last issued its earnings results on Thursday, May 8th. The company reported ($0.12) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.37) by $0.25. As a group, sell-side analysts anticipate that HilleVax, Inc. will post -2.64 earnings per share for the current year.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reissued a "neutral" rating and issued a $2.00 target price on shares of HilleVax in a report on Monday, March 31st. Six investment analysts have rated the stock with a hold rating, According to MarketBeat, HilleVax currently has a consensus rating of "Hold" and a consensus target price of $3.00.

HilleVax Profile

HilleVax, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was formerly known as MokshaCo, Inc and changed its name to HilleVax, Inc in February 2021.